

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/189910 A1

(43) International Publication Date
27 December 2013 (27.12.2013)

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 35/02* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/EP2013/062579

(22) International Filing Date:
18 June 2013 (18.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/662,933 22 June 2012 (22.06.2012) US
12173093.1 22 June 2012 (22.06.2012) EP
12188814.3 17 October 2012 (17.10.2012) EP

(71) Applicant: **BASF SE** [DE/DE]; 67056 Ludwigshafen (DE).

(71) Applicant (for CY only): **BASF SCHWEIZ AG** [CH/CH]; Klybeckstrasse 141, CH-4057 Basel (CH).

(72) Inventors: **CHIDO, Tiziana**; C4 12, 68159 Mannheim (DE). **HELLMANN, Rolf**; Kehrstr. 12A, 67363 Lustadt (DE). **VOSEN, Marcus**; Wachenheimer Strasse 8, 67117 Limburgerhof (DE). **SALVADOR, Beate**; Trifelsring 9, 67158 Ellerstadt (DE). **HAFNER, Andreas**; Balkenweg 23, CH-4460 Gelterkinden (CH). **HINTERMANN, Tobias**; Lehmgrubenweg 12, CH-4106 Therwil (CH).

(74) Agent: **UPSCHULTE, Manfred**; BASF Schweiz AG, IP Department, P.O. Box, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MULTICOMPONENT CRYSTALS COMPRISING IMATINIB MESILATE AND SELECTED CO-CRYSTAL FORMERS

(57) Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1- piperazinyl) methyl] -N -[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]- benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.




WO 2013/189910 A1

Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers

Description

5 The present invention relates to multicomponent systems comprising imatinib mesilate and selected co-crystal formers, to pharmaceutical preparations comprising said systems, and specifically to homogenous crystalline phases (co-crystals) comprising imatinib mesilate and selected co-crystal formers. The invention also relates to processes for preparing said multicomponent systems and crystalline phases. The invention also relates to compositions comprising said multicomponent systems or crystalline phases and pharmaceutically acceptable carrier and to methods of using said multicomponent systems or crystalline phases to treat a disease condition wherein tyrosine kinase inhibition is beneficial.

15 The active substance imatinib mesilate is the mesylate salt form of imatinib, the synonymus of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt, specifically shown in formula (1):



20

(1)

Imatinib mesilate is known to act as as a tyrosine kinase inhibitor that selectively inhibits the Abl tyrosine kinases. It is useful for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs) and is marketed as Glivec® (Europe, Australia, Latin America) or Gleevec® (USA). Imatinib mesilate may have different polymorphic phases.

25

In WO 99/03854 are disclosed crystalline forms, hereafter referred as form α and form β of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt.

- 5 WO 04/106326 discloses the hydrate crystalline form, hereafter referred as form H1, the corresponding hydrate amorphous phase and a pharmaceutical composition comprising the amorphous imatinib mesilate hydrate.

- 10 WO 05/077933, WO 06/054314, WO 07/059963, WO 07/023182 and WO 07/136510 disclose further crystalline forms of imatinib mesilate, the processes to prepare them and the corresponding pharmaceutical compositions.

- 15 WO 10/081443 discloses dosage forms of tyrosine kinase inhibitors. Co-crystals comprising imatinib mesilate and arginine, lactose, guanidine, n-methylglucamin, histidine, glucose, lactose, fructose, alginic acid, pectin 4 are mentioned.

- 20 WO 11/023146 discloses a process to generate imatinib mesilate polymorphs by crystallization in aqueous inorganic solution. Cocystals with the inorganic salts NaCl, KCl, KBr are described.

- 25 Though there are a number of solid forms of imatinib mesilate known, there exists a need for other solid forms, especially crystalline forms, of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt for sufficient diversity on crystalline materials to optimize manufacture, improve hygroscopic behavior, dissolution rate, formulation and biological efficiency.

Summary of the Invention:

- 30 The invention provides the description of novel crystalline forms of imatinib mesilate comprising imatinib mesilate and selected co-crystal formers, and processes for manufacture thereof.

- 35 The said crystalline forms show improved physical and/or biological characteristics which may assist in the manufacture or formulation of the active compound and to achieve the purity levels and uniformity required for regulatory approval. The said crystalline form may possess improved pharmacological characteristics, for example, im-

proved bioavailability and/or hygroscopic behaviour, thus offering enhanced possibilities to modulate and design improved drug products.

Detailed Description of the Invention:

5

The solid form of the invention is a composite comprising two components, which are the adduct salt of imatinib with methanesulfonic acid (i.e. imatinib mesilate) and a carbonic acid compound (i.e. carboxylic acid) selected from benzoic acid, fumaric acid and succinic acid, within one single phase. Imatinib mesilate and one of benzoic acid, fumaric acid, succinic acid are present in the same solid phase, preferably in the same crystalline phase, i.e. forming a co-crystal (the pKa values of the present carboxylic acid component are from a range defining the product as a co-crystal rather than a salt).

10

15

The molar ratio of imatinib mesilate and benzoic acid, fumaric acid or succinic acid is generally in the range from about 2:1 to about 1:2. The term "about" in this context refers to small deviations in the molar ratio, which may lead to deviations from the given ratio typically in the range of 10%. In particular, the molar ratio typically is about 1:2 (e.g. ranging from 1:1.8 to to 1:2.2) for the imatinib mesilate and benzoic acid cocrystal, and from 1.5:1 to 1:1.5 and especially about 1:1 (i.e. from 1.1:1 to 1:1.1) for the imatinib mesilate and fumaric acid, or imatinib mesilate and succinic acid cocrystal. Similarly, the composition of the present invention may show a deviation from the original 1:1 molar ratio, which may result in that the component imatinib mesitylate in the present product shows a final molar ratio of imatinib : methysulfonic acid from the range 1.1 : 1 to 0.9 : 1, especially 1.1 : 1 to 1:1.

20

25

The invention thus includes

30

a) a multicomponent molecular crystal containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and benzoic acid, especially

35

b) an anhydrous crystalline form as defined under (a) consisting essentially of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and benzoic acid, having stoichiometric ratio 1:2;

40

c) a multicomponent molecular crystal containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and fumaric acid, especially

- d) an anhydrous crystalline form as defined under (c) consisting essentially of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and fumaric acid, having stoichiometric ratio 1:1;
- 5 e) a multicomponent molecular crystal containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and succinic acid, especially
- 10 f) an anhydrous crystalline form as defined under (e) consisting essentially of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and succinic acid, having stoichiometric ratio 1:1.
- 15 The co-crystal with benzoic acid, especially the solid form defined under (a), may be further characterized by its melting range 117 – 137°C, preferably 124 – 130 °C, or its m.p. of 127°C. The present solid form provides better dissolution characteristic and hygroscopic behavior, when compared with the imatinib mesilate forms previously known.
- 20 Imatinib mesilate and benzoic acid are present in the same solid phase, preferably in the same crystalline phase, i.e. forming a co-crystal. The preferred novel crystalline form generally exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 15.09 (vs), 11.37 (vs), 10.88 (m), 9.74 (m), 6.96 (m), 5.61 (m), 5.41 (s), 5.26 (m), 4.87 (vs), 4.57 (vs), 4.48 (m), 4.35 (vs), 4.25 (s), 25 4.16 (m), 4.02 (m), 3.98 (m), 3.78 (m), 3.51 (m).
- Solid form defined under (a) comprises comprises a crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and benzoic acid, having stoichiometric ratio of 30 about 1:2, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

d value	Intensity
[Angstroem]	
22.63	w
15.09	vs
11.37	vs
10.88	m
9.74	m
6.96	m

6.14	w
5.99	w
5.61	m
5.41	s
5.26	m
4.87	vs
4.69	w
4.57	vs
4.48	m
4.35	vs
4.25	s
4.16	m
4.02	m
3.98	m
3.78	m
3.66	w
3.59	w
3.51	m

Here and in the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

Also preferred is the crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and benzoic acid, having stoichiometric ratio of about 1:2, which exhibits a characteristic X-ray powder diffraction pattern substantially as shown in Fig. 1.

The co-crystal with fumaric acid, especially the solid form defined under (c), may be further characterized by its melting point of 186°C (e.g. from melting range 176 – 196°C, especially 183 – 189 °C). The present solid form provides better hygroscopic behavior, when compared with the imatinib mesilate forms previously known.

Imatinib mesilate and fumaric acid are present in the same solid phase, preferably in the same crystalline phase, i.e. forming a co-crystal. The preferred novel crystalline form generally exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 19.54 (m), 13.11 (vs), 12.08 (m), 9.85 (s), 9.05 (m).

Solid form defined under (c) comprises a crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and fumaric acid, having stoichiometric ratio 1:1,

which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

d value	Intensity
[Angstroem]	
19.54	m
13.11	vs
12.08	m
9.85	S
9.05	m
8.27	w
5.32	w
4.95	w
4.50	w
4.36	w
4.20	w
3.81	w
3.31	w

Here and in the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

Also preferred is the crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and fumaric acid, having stoichiometric ratio 1:1, which exhibits a characteristic X-ray powder diffraction pattern substantially as shown in Fig. 3.

The co-crystal with succinic acid, especially the solid form defined under (e) may be further characterized by its melting range of 140°C – 160 °C. The relatively broad melting range and a further endothermic transition in the range 90 – 100 °C indicate the existence of polymorphic phases of the defined multicomponent system. The present solid form provides better dissolution characteristic and hygroscopic behavior, when compared with the imatinib mesilate forms previously known.

Imatinib mesilate and succinic acid are present in the same solid phase, preferably in the same crystalline phase, i.e. forming a co-crystal. The preferred novel crystalline form generally exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 12.68 (vs), 9.38 (s), 5.34 (m), 4.68 (vs), 4.58 (s), 4.50 (s), 4.41 (s), 4.21 (m), 4.07 (m).

- Solid form defined under (e) comprises a crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and succinic acid, having stoichiometric ratio 1:1, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

d value [Angstroem]	Intensity
18.96	w
12.68	vs
9.38	s
8.23	w
7.64	w
7.17	w
6.86	w
6.49	w
6.28	w
5.34	m
4.68	vs
4.58	s
4.50	s
4.41	s
4.21	m
4.07	m
3.85	w
3.44	w
3.22	w

Here and in the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

- Also preferred is the crystalline form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and succinic acid, having stoichiometric ratio 1:1, which exhibits a characteristic X-ray powder diffraction pattern substantially as shown in Fig. 5.

15

Another object of the invention is a process for the preparation of crystalline form defined under (a) to (f) which comprises the steps of

- i) providing a solution of imatinib mesilate (e.g. imatinib mesilate form β) and benzoic acid, fumaric acid or succinic acid in a suitable solvent,
- ii) cooling or concentrating the solution provided in steps (i), and

20

iii) separating the precipitate and drying.

Suitable solvents that may be used in step (i) are typically organic solvents having a water miscibility of at least 10 % at room temperature ("polar organic solvents") or mix-
5 tures of water with polar organic solvents. Solutions according to steps (i) preferably are concentrated solutions. The concentration of imatinib mesilate may range from 0.1 to about 300 mg/ml of solvents (including water), preferably from 20 to 200 mg/ml.

The process is preferably carried out in the temperature range 25-100°C, preferably
10 25-80°C, for example at ambient temperature. In a preferred process, step (i) and (ii) are carried out at a temperature from the range 25-80°C or the mixture is heated to a temperature from said range, e.g. about 80°C, especially in case that solid imatinib mesilate provided in step (i), with forming a solution. The solution thus tempered is then preferably cooled before step (iii).

15 Ambient temperature means in the context of the invention a temperature range at room temperature or slightly above, comprising 20 to 30 °C and preferably about 23 to 26 °C.

20 Cocrystal defined under a), c) and e) are isolated by filtering off the crystals and drying or by evaporation of the solvent, e.g. in vacuum, an inert gas flow or both at ambient temperature, or elevated temperatures up to 80°C.

25 Cocrystal defined under a), c) and e) enable to improve the hygroscopic behaviour of imatinib mesilate, i.e. providing a better long-term stability over a broad range of humidity range with respect to the previously known imatinib mesilate forms.

30 Cocrystal defined under a) and e) enables to improve the dissolution characteristics of imatinib mesilate, i.e. providing a better dissolution kinetic profile with respect to the previously known imatinib mesilate form.

35 Cocrystal defined under a), c) and e) are thermodynamically stable and can be dried at elevated temperatures, e.g. below 80°C, and is obtained as a fine powder with typical particle size distributions with the median size between 1 and 50 µm, preferably between 1 to 10 µm. This particle size range ensures a fast dissolution profile, while retaining the favourable handling properties in the formulation process.

40 Cocrystal defined under a) to e) may be used in pharmaceutical compositions in the same way as other forms of imatinib mesilate previously known.

The present invention is also directed to a pharmaceutical composition comprising a solid form containing benzoic acid, fumaric acid or succinic acid and 4-[(4-methyl-1-

piperaziny] methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and a pharmaceutically acceptable carrier or diluent.

- 5 The amount of solid (especially crystalline) forms of 4-[(4-methyl-1-piperaziny] methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt thereof substantially depends on type of formulation and desired dosages during administration time periods. The amount in an oral formulation may be from 0.1 to 200 mg, preferably from 0.5 to 100 mg, and more preferably from 1 to 50
10 mg.

The present invention thus further provides a therapeutic method for producing an disease condition wherein tyrosine kinase inhibition is beneficial, which method comprises administering in need of such therapy, an effective amount of the crystalline material,
15 especially co-crystal, of the invention as described above.

Oral formulations may be solid formulations such as capsules, tablets, pills and troches, or liquid formulations such as aqueous suspensions, elixirs and syrups. Solid and liquid formulations encompass also incorporation of the present solid form into liquid or
20 solid food.

The solid forms according to the invention may be directly used as powders (micronized particles), granules, suspensions or solutions, or they may be combined together with other pharmaceutically acceptable ingredients in admixing the components and optionally finely divide them, and then filling capsules, composed for example from
25 hard or soft gelatine, compressing tablets, pills or troches, or suspend or dissolve them in carriers for suspensions, elixirs and syrups. Coatings may be applied after compression to form pills.

30 Pharmaceutically acceptable ingredients are well known for the various types of formulation and may be for example binders such as natural or synthetic polymers, excipients, lubricants, surfactants, sweetening and flavouring agents, coating materials, preservatives, dyes, thickeners, adjuvants, antimicrobial agents and carriers for the various formulation types.

35 Examples for binders are gum tragacanth, acacia, starch, gelatine, and biological degradable polymers such as homo- or co-polyesters of dicarboxylic acids, alkylene glycols, polyalkylene glycols and/or aliphatic hydroxyl carboxylic acids; homo- or co-polyamides of dicarboxylic acids, alkylene diamines, and/or aliphatic amino carboxylic
40 acids; corresponding polyester-polyamide-co-polymers, polyanhydrides, polyorthoesters, polyphosphazene and polycarbonates. The biological degradable polymers may be linear, branched or crosslinked. Specific examples are poly-glycolic acid, poly-lactic

acid, and poly-d,l-lactide/glycolide. Other examples for polymers are water-soluble polymers such as polyoxaalkylenes (polyoxaethylene, polyoxapropylene and mixed polymers thereof, poly-acrylamides and hydroxylalkylated polyacrylamides, poly-maleic acid and esters or -amides thereof, poly-acrylic acid and esters or -amides thereof, 5 poly-vinylalcohol und esters or -ethers thereof, poly-vinylimidazole, poly-vinylpyrrolidon, und natural polymers like chitosan, carragenan or hyaluronic aid.

Examples for excipients are phosphates such as dicalcium phosphate.

10 Examples for lubricants are natural or synthetic oils, fats, waxes, or fatty acid salts like magnesium stearate.

Surfactants may be anionic, anionic, amphoteric or neutral. Examples for surfactants are lecithin, phospholipids, octyl sulfate, decyl sulfate, dodecyl sulfate, tetradecyl sulfate, 15 hexadecyl sulfate and octadecyl sulfate, Na oleate or Na caprate, 1-acylaminoethane-2-sulfonic acids, such as 1-octanoylaminoethane-2-sulfonic acid, 1-decanoylaminoethane-2-sulfonic acid, 1-dodecanoylaminoethane-2-sulfonic acid, 1-tetradecanoylaminoethane-2-sulfonic acid, 1-hexadecanoylaminoethane-2-sulfonic acid, and 1-octadecanoylaminoethane-2-sulfonic acid, and taurocholic acid and tauro-20 deoxycholic acid, bile acids and their salts, such as cholic acid, deoxycholic acid and sodium glycocholates, sodium caprate or sodium laurate, sodium oleate, sodium lauryl sulphate, sodium cetyl sulphate, sulfated castor oil and sodium dioctylsulfosuccinate, cocamidopropylbetaine and laurylbetaine, fatty alcohols, cholesterol, glycerol mono- or -distearate, glycerol mono- or -dioleate and glycerol mono- or -dipalmitate, and poly-25 oxyethylene stearate.

Examples for sweetening agents are sucrose, fructose, lactose or aspartam.

Examples for flavouring agents are peppermint, oil of wintergreen or fruit flavours like 30 cherry or orange flavour.

Examples for coating materials gelatine, wax, shellac, sugar or biological degradable polymers.

35 Examples for preservatives are methyl or propylparabens, sorbic acid, chlorobutanol, phenol and thimerosal.

Examples for adjuvants are fragrances.

40 Examples for thickeners are synthetic polymers, fatty acids and fatty acid salts and esters and fatty alcohols.

Examples for liquid carriers are water, alcohols such as ethanol, glycerol, propylene glycol, liquid polyethylene glycols, triacetin and oils. Examples for solid carriers are talc, clay, microcrystalline cellulose, silica, alumina and the like.

- 5 The formulation according to the invention may also contain isotonic agents, such as sugars, buffers or sodium chloride.

Colloidal silicon dioxide may be contained for use as a glidant, carrier, desiccant. Crospovidone may be contained for use as a disintegrant. Hydroxypropyl methylcellulose
10 may be contained for use as a binder. Magnesium stearate may be contained for use as a lubricant. Microcrystalline cellulose may be contained for use as a carrier.

Pharmaceutical compositions of the present invention can optionally be mixed with other forms of imatinib mesylate and/or other active ingredients. In
15 addition, pharmaceutical compositions of the present invention can contain inactive ingredients such as diluents, carriers, fillers, bulking agents, binders, disintegrants, disintegration inhibitors, absorption accelerators, wetting agents, lubricants, glidants, surface active agents, flavoring agents, and the like.

Diluents increase the bulk of a solid pharmaceutical composition and
20 can make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), micro:fine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrans, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate,
25 kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, or talc.

Carriers for use in the pharmaceutical compositions may include, but are not limited to, lactose, white sugar, sodium chloride, glucose, urea, starch, calcium
30 carbonate, kaolin, crystalline cellulose, or silicic acid.

Binders help bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include for example acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil,
35 hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel~, hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone~, pregelatinized starch, sodium alginate, or starch.

41

40 Disintegrants can increase dissolution. Disintegrants include, for example, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose~, colloidal silicon dioxide, croscarmellose

sodium, croscopovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrillin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab~ and starch.

- 5 Disintegration inhibitors may include, but are not limited to, white sugar, stearin, coconut butter, hydrogenated oils, and the like.

Absorption accelerators may include, but are not limited to, quaternary ammonium base, sodium laurylsulfate, and the like.

- 10 Wetting agents may include, but are not limited to, glycerin, starch, and the like. Adsorbing agents may include, but are not limited to, starch, lactose, kaolin, bentonite, colloidal silicic acid, and the like.

- A lubricant can be added to the composition to reduce adhesion and ease release of the product from a punch or die during tableting. Lubricants include for example magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, 15 polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.

- Glidants can be added to improve the flowability of non-compacted solid composition and improve the accuracy of dosing. Excipients that can function 20 as glidants include for example colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.

- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present 25 invention include for example maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.

- Tablets can be further coated with commonly known coating materials such as sugar coated tablets, gelatin film coated tablets, tablets coated with enteric coatings, tablets coated with films, double layered tablets, and multi-layered tablets. 30

Capsules can be coated with shell made, for example, from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.

- Solid and liquid compositions can also be dyed using any 35 pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.

- In liquid pharmaceutical compositions of the present invention, the imatinib mesylate of the present invention is suspended together with any other solid ingredients, which may be dissolved or suspended, in a liquid carrier, such as water, 40 vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin. In suspension the imatinib mesylate retains its crystalline form.

Liquid pharmaceutical compositions can contain emulsifying agents to

disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.

Liquid pharmaceutical compositions of the present invention can also contain viscosity enhancing agents to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include for example acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum. Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar can be added to improve the taste.

Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid can be added at safe levels to improve storage stability.

A liquid pharmaceutical composition according to the present invention can also contain a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate.

Selection of excipients and the amounts to use can be readily determined by an experienced formulation scientist in view of standard procedures and reference works known in the art.

A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, which causes the powders to clump up into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate can then be tableted or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.

A tableting composition can be prepared conventionally by dry blending. For instance, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can be compressed subsequently into a tablet.

As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules.

Excipients that are particularly well-suited to direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression

tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.

A capsule filling of the present invention can comprise any of the aforementioned blends and granulates that were described with reference to tableting, only they are not subjected to a final tableting step.

When shaping the pharmaceutical composition into pill form, any commonly known excipient used in the art can be used. For example, carriers include, but are not limited to, lactose, starch, coconut butter, hardened vegetable oils, kaolin, talc, and the like. Binders used include, but are not limited to, gum arabic powder, tragacanth gum powder, gelatin, ethanol, and the like. Disintegrating agents

used include, but are not limited to, agar, laminaria, and the like. For the purpose of shaping the pharmaceutical composition in the form of suppositories, any commonly known excipient used in the art can be used. For example, excipients include, but are not limited to, polyethylene glycols, coconut butter, higher alcohols, esters of higher alcohols, gelatin, semisynthesized glycerides, and the like.

When preparing injectable pharmaceutical compositions, solutions and suspensions are sterilized and are preferably made isotonic to blood. Injection preparations may use carriers commonly known in the art. For example, carriers for injectable preparations include, but are not limited to, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, and fatty acid esters of polyoxyethylene sorbitan. One of ordinary skill in the art can easily determine with little or no experimentation the amount of sodium chloride, glucose, or glycerin necessary to make the injectable preparation isotonic. Additional ingredients, such as dissolving agents, buffer agents, and analgesic agents may be added. If necessary, coloring agents, preservatives, perfumes, seasoning agents, sweetening agents, and other medicines may also be added to the desired preparations during the treatment.

The amount of imatinib mesylate of the present invention contained in a pharmaceutical composition according to the present invention is not specifically restricted; however, the dose should be sufficient to treat, ameliorate, or reduce the condition.

The solid forms according to the invention may also be formulated as effervescent tablet or powder, which disintegrate in an aqueous environment to provide a drinking solution.

A syrup or elixir may contain the polymorph of the invention, sucrose or fructose as sweetening agent a preservative like methylparaben, a dye and a flavouring agent.

The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administra-

tion. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

5

Dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and lozenges as well as liquid suspensions and elixirs. While the description is not intended to be limiting, the invention is also not intended to pertain to true solutions of imatinib mesilate whereupon the properties that distinguish the solid forms of imatinib mesilate are lost. However, the use of the novel forms to prepare such solutions is considered to be within the contemplation of the invention.

10

Capsule dosages, of course, will contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material. Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating. The enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl-cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers and/or extending agents. A coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric-coating.

15

20

Slow release formulations may also be prepared from the crystal form according to the invention in order to achieve a controlled release of the active agent in contact with the body fluids in the gastro intestinal tract, and to provide a substantial constant and effective level of the active agent in the blood plasma. The crystal forms may be embedded for this purpose in a polymer matrix of a biological degradable polymer, a water-soluble polymer or a mixture of both, and optionally suitable surfactants. Embedding can mean in this context the incorporation of micro-particles in a matrix of polymers. Controlled release formulations are also obtained through encapsulation of dispersed micro-particles or emulsified micro-droplets via known dispersion or emulsion coating technologies.

25

30

The crystal forms of the invention are also useful for administering a combination of therapeutic effective agents to an animal. Such a combination therapy can be carried out in using at least one further therapeutic agent which can be additionally dispersed or dissolved in a formulation.

35

The crystal forms of this invention and its formulations respectively can be also administered in combination with other therapeutic agents that are effective to treat a given condition to provide a combination therapy.

40

The crystal forms and the pharmaceutical composition according to the invention are highly suitable for effective treatment of disorders in connection with need of inhibiting the Abl tyrosine kinases. Imatinib mesilate as well as the present forms, especially co-crystals, thereof and pharmaceutical composition are useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors.

An object of the invention is also a therapeutic method for producing an Abl tyrosine kinase inhibiting effect in a mammal comprising administering to a mammal in need of such therapy, an effective amount of the present composite containing benzoic acid, fumaric acid or succinic acid and 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt.

The crystalline forms of the invention may be used as single component or as mixtures with other solid forms, which may be crystalline or amorphous.

As to the previously known polymorphic forms of imatinib mesilate it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of imatinib mesilate. Preferably, such an amount of the novel polymorphic forms of imatinib mesilate is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.

Another object of the invention is a method of delivering a solid form of 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt to a host, which method comprises administering to a host an effective amount of said solid forms, according to the invention.

A further object of the invention is the use the said crystalline forms containing benzoic acid, fumaric acid or succinic acid and 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt, for the manufacture of a medicament useful in the treatment of disorders in connection with need of inhibiting the Abl tyrosine kinases and especially useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors.

The following examples illustrate the invention.

Wherever noted, room temperature depicts a temperature from the range 18-23°C; percentages are given by weight, if not indicated otherwise.

Abbreviations:

HPLC	high pressure liquid chromatography
NMR	nuclear magnetic resonance
FTIR	Fourier-transformation infrared spectrometry

	PXRD	powder x-ray diffraction
	XRPD	x-ray powder diffractogram
	r.h.	relative humidity (air, if not indicated otherwise)
	m.p.	melting point
5	TG	thermogravimetry
	v/v	volume by volume

Instrumental

Powder X-ray diffraction: PXRD is carried out with a Panalytical X'Pert Pro X-ray diffractometer using $\text{Cu}_{\text{K}\alpha}$ radiation in reflection (Bragg-Brentano) geometry. 2θ values are accurate within an error of ± 0.1 - 0.2° . The samples are prepared without any special treatment other than the application of slight pressure to get a flat surface. The tube voltage is 40 kV and current was 40 mA. The XRPD diffractograms are collected at room temperature in the geometry in the range from $2\theta = 3^\circ$ - 33°C with increments of 0.0167°C .

Thermogravimetry:

The thermo gravimetric measurements are carried out with a Mettler Toledo TGA/SDTA851e module. The thermal behaviour is analysed in the range 30 – 250°C by using a heating rate of $5^\circ\text{C}/\text{min}$ and a stream of nitrogen flowing at 150 ml/ during the experiment.

DSC:

DSC is performed on a Mettler Toledo DSC 822e module. The sample is placed in crimped but vented aluminium pans (sample size was 10 mg). The thermal behaviour is analysed in the range 30 – 250°C by using a heating rate of $5^\circ\text{C}/\text{min}$ and a stream of nitrogen flowing at 150 ml/ during the experiment.

^1H -NMR:

The ^1H -NMR spectra are recorded on a Bruker DPX 300 spectrometer.
Solvent: DMSO- d_6 .

Experimental

Solvents: For all experiments, Fluka or Merck grade solvents are used.

Co-crystal formers used are

Benzoic Acid obtained from ACROS ORGANICS (#221802500);

Fumaric Acid obtained from ALDRICH (#F1,935-3);

Succinic Acid obtained from MERCK (#8.22260.0250).

5

For all experiments, imatinib mesilate form β is used, showing a PXRD as of Fig. 2/3 of WO99/03854; m.p. 225°C. Imatinib mesilate form β is prepared as disclosed in WO99/03854, example 1.

10 **Example 1: Preparation of the imatinib mesilate and benzoic acid**

334 mg of imatinib mesilate and 166 mg of benzoic acid are suspended in 1 mL of the mixture (v/v) ethanol/water 4:1 at room temperature. The system is stirred for 4 days at room temperature. The resulting suspension is filtered and dried in vacuum for 12 hours. XRPD shows the pattern of Figure 1. DSC in a closed sample pan shows an
15 endothermal effect with a peak temperature of about 127 °C (65 J/g). ¹H-NMR (measured in DMSO-d₆) shows the spectrum of a mixture of imatinib mesilate and benzoic acid (molar ratio imatinib mesilate salt : benzoic acid 1:2).

Example 2: Preparation of the imatinib mesilate and fumaric acid

20 810 mg of imatinib mesilate and 190 mg of fumaric acid are suspended in 20 mL of the mixture (v/v) ethanol/water 96:4 at room temperature. A solution is obtained after re-fluxing at 80 °C under stirring for 30 minutes, followed by the precipitation of a yellow solid. The mixture is then cooled down to room temperature. The suspension formed is filtered and dried in vacuum for 12 hours. The yield is approximately 68%. XRPD
25 shows the pattern of Figure 3. DSC in a closed sample pan shows an endothermal effect with a peak temperature of 186°C (79 J/g). ¹H-NMR (measured in DMSO-d₆) shows the spectrum of a mixture of imatinib mesilate and fumaric acid (molar ratio imatinib mesilate salt : fumaric acid 1:1).

30 **Example 3: Preparation of the imatinib mesilate and succinic acid**

807 mg of imatinib mesilate and 193 mg of succinic acid are suspended in 5 mL of the mixture (v/v) ethanol/water 4:1. The system is stirred for 1 hour at 60 °C. A clear solution is obtained. The solution is cooled down to room temperature and no precipitation is observed. The solid is isolated by removing the solvent in vacuum at room temperature.
35 XRPD shows the pattern of Figure 5. DSC in a closed sample pan shows two endothermal effects with a first peak in the temperature range 90-100 °C and a second

peak in the temperature range 140 – 160 °C. ¹H-NMR (measured in DMSO-d₆) shows the spectrum of a mixture of imatinib mesilate and succinic acid (molar ratio imatinib mesilate salt : succinic acid 1:1).

5 Brief description of Figures:

Figure 1: Powder X-Ray Diffraction pattern of imatinib mesilate and benzoic acid 1:2 co-crystal

10 **Figure 2:** DSC trace of imatinib mesilate and benzoic acid 1:2 co-crystal (range: 30-250°C)

Figure 3: Powder X-Ray Diffraction pattern of imatinib mesilate and fumaric acid 1:1 co-crystal

15

Figure 4: DSC trace of imatinib mesilate and fumaric acid 1:1 co-crystal (range: 30-250°C)

Figure 5: Powder X-Ray Diffraction pattern of imatinib mesilate and succinic acid 1:1 co-crystal

20

Figure 6: DSC trace of imatinib mesilate and succinic acid 1:1 co-crystal (range: 30-250°C)

25

Claims

1. A crystalline material comprising 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt
5 and a carboxylic acid compound selected from benzoic acid, fumaric acid, succinic acid, especially within the same crystalline phase.
2. Crystalline material of claim 1 (co-crystal) containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide me-
10 thanesulfonic acid salt and the carboxylic acid compound within the same crystalline phase in the molar ratio ranging from about 2:1 to about 1:2, especially containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and benzoic acid in a molar ratio ranging from 1:1.8 to 1:2.2; or 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and
15 fumaric acid or succinic acid in a molar ratio ranging from 1.5:1 to 1:1.5.
3. Crystalline material of claim 1 or 2 (co-crystal) containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide
20 methanesulfonic acid salt and benzoic acid within the same crystalline phase, which is characterized by exhibiting a X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 15.09, 11.37, 10.88, 9.74, 6.96, 5.61, 5.41, 5.26, 4.87, 4.57, 4.48, 4.35, 4.25, 4.16, 4.02, 3.98, 3.78, 3.51.
- 25 4. Crystalline material according to any of claims 1 to 3 (co-crystal), which exhibits a X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

d value	Intensity
[Angstroem]	
22.63	w
15.09	vs
11.37	vs
10.88	m
9.74	m
6.96	m
6.14	w
5.99	w

5.61	m
5.41	s
5.26	m
4.87	vs
4.69	w
4.57	vs
4.48	m
4.35	vs
4.25	s
4.16	m
4.02	m
3.98	m
3.78	m
3.66	m
3.59	w
3.51	m

5. A Crystalline material (co-crystal) according to claim 1 or 2 containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and fumaric acid, exhibiting a X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 19.54, 13.11, 12.08, 9.85, 9.05.

6. A Crystalline material according to any of claims 1, 2 and 5, which exhibits a X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

d value [Angstroem]	Intensity
19.54	m
13.11	vs
12.08	m
9.85	s
9.05	m
8.27	w
5.33	w
4.95	w
4.50	w
4.36	w

4.20	w
3.81	w
3.31	w

7. A Crystalline material according to claim 1 or 2 (co-crystal) containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and succinic acid, exhibiting a X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å): 12.68, 9.38, 5.34, 4.68, 4.58, 4.50, 4.41, 4.21, 4.07.

8. A Crystalline material according to any of claims 1, 2, 7, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) as shown in the below table:

10

d value [Angstroem]	Intensity
18.96	w
12.68	vs
9.38	s
8.23	w
7.64	w
7.17	w
6.86	w
6.49	w
6.28	w
5.34	m
4.68	vs
4.58	s
4.50	s
4.41	s
4.21	m
4.07	m
3.85	w
3.44	w
3.22	w

9. Crystalline material according to any of claims 1 to 8, comprising a multicomponent molecular crystal containing 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and one of benzoic acid, fumaric acid or succinic acid, which exhibits a characteristic X-ray powder diffraction pattern essentially as exhibited in Figure 1 and a characteristic DSC

15

trace as exhibited in Figure 2; or which exhibits a characteristic X-ray powder diffraction pattern essentially as exhibited in Figure 3 and a characteristic DSC trace as exhibited in Figure 4; or which exhibits a characteristic X-ray powder diffraction pattern essentially as exhibited in Figure 5 and a characteristic DSC trace as exhibited in Figure 6.

5

10. Process for the preparation of a solid form according to any of claims 1 to 9, which process comprises the steps of

a) providing a solution or suspension of imatinib mesilate, especially of imatinib mesilate form β , and benzoic acid, fumaric acid or succinic acid in a suitable solvent,

10 b) optionally cooling or concentrating the solution provided in step (a), and

c) separating the precipitate and drying.

11. Pharmaceutical composition comprising a crystalline material comprising 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt and a carboxylic acid compound selected from benzoic acid, fumaric acid, succinic acid, especially co-crystal according to any of claims 2 to 9, and a pharmaceutically acceptable carrier or diluent.

15

12. Solid pharmaceutical composition according to claim 11,

20

wherein the carboxylic acid compound is benzoic acid and which is characterized by at least one characteristic peak in an x-ray powder diffractogram expressed in d-values (\AA) selected from 15.09, 11.37, 10.88, 9.74, 6.96, 5.61, 5.41, 5.26, 4.87, 4.57, 4.48, 4.35, 4.25, 4.16, 4.02, 3.98, 3.78, 3.51; or

wherein the carboxylic acid compound is fumaric acid and which is characterized by at least one characteristic peak in an x-ray powder diffractogram expressed in d-values (\AA) selected from 19.54, 13.11, 12.08, 9.85, 9.05; or

25

wherein the carboxylic acid compound is fumaric acid and which is characterized by at least one characteristic peak in an x-ray powder diffractogram expressed in d-values (\AA) selected from 12.68, 9.38, 5.34, 4.68, 4.58, 4.50, 4.41, 4.21, 4.07.

30

13. A method of delivering 4-[(4-methyl-1-piperazinyl) methyl] – N – [4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl]-benzamide methanesulfonic acid salt, which method comprises administering to a host an effective amount of a crystalline material according to any of claims 1 to 9.

35

14. Use of a crystalline material according to any of claims 1 to 9 for the manufacture of a medicament.

15. Use according to claim 14, wherein the medicament is useful in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs) in connection with need of inhibiting the Abl tyrosine kinases.

40




Figure 1. XRPD pattern of the co-crystal comprising imatinib mesilate and benzoic acid




Figure 2. DSC trace of the co-crystal comprising imatinib mesilate and benzoic acid




Figure 3. XRPD pattern of the co-crystal comprising imatinib mesilate and fumaric acid




Figure 4. DSC trace of the co-crystal comprising imatinib mesilate and fumaric acid




Figure 5. XRPD pattern of the co-crystal comprising imatinib mesilate and succinic acid




Figure 6. DSC trace of the co-crystal comprising imatinib mesilate and succinic acid

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2013/062579

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/062579

A. CLASSIFICATION OF SUBJECT MATTER INV. C07D401/04 A61K31/505 A61P35/02 ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/081443 A2 (ZENTIVA K S [CZ]; KRAL VLADIMIR [CZ]; JAMPILEK JOSEF [CZ]; HAVLICEK JA) 22 July 2010 (2010-07-22) cited in the application claims 1,5; examples 4,27,31 -----	1-15
X	WO 99/03854 A1 (NOVARTIS AG [CH]; NOVARTIS ERFIND VERWALT GMBH [AT]; ZIMMERMANN JUERG) 28 January 1999 (1999-01-28) cited in the application page 17; examples 4,6 -----	1
Y	WO 2008/054609 A2 (UNIV MICHIGAN [US]; RODRIGUEZ-HORNEDO NAIR [US]) 8 May 2008 (2008-05-08) paragraphs [0044], [0060], [0061]; claim 1 ----- -/--	1-15
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
23 July 2013		31/07/2013
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Grassi, Damian

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2013/062579

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 2004/078163 A2 (TRANSFORM PHARMACEUTICALS INC [US]; UNIV SOUTH FLORIDA [US]; UNIV MICH) 16 September 2004 (2004-09-16) pages 95,97 page 105; claim 1</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/062579

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010081443	A2	22-07-2010	NONE
WO 9903854	A1	28-01-1999	AR 016351 A1 04-07-2001
			AR 043266 A2 27-07-2005
			AT 251152 T 15-10-2003
			AU 740713 B2 15-11-2001
			AU 8975998 A 10-02-1999
			BR 9810920 A 15-08-2000
			CA 2296604 A1 28-01-1999
			CN 1264375 A 23-08-2000
			CO 4940418 A1 24-07-2000
			CZ 20000149 A3 17-05-2000
			DE 69818674 D1 06-11-2003
			DE 69818674 T2 12-08-2004
			DK 998473 T3 02-02-2004
			EP 0998473 A1 10-05-2000
			ES 2209194 T3 16-06-2004
			HK 1028599 A1 30-04-2004
			HU 0003230 A2 28-06-2001
			ID 24093 A 06-07-2000
			IL 133906 A 05-07-2006
			IL 168972 A 01-08-2006
			IL 174082 A 31-05-2010
			JP 3276359 B2 22-04-2002
			JP 2001510192 A 31-07-2001
			MY 128664 A 28-02-2007
			MY 129772 A 30-04-2007
			NO 331016 B1 12-09-2011
			NO 20000227 A 17-01-2000
			NZ 502295 A 21-12-2001
			PL 338129 A1 25-09-2000
			PT 998473 E 27-02-2004
			RU 2208012 C2 10-07-2003
			SK 287276 B6 07-05-2010
			SK 432000 A3 12-06-2000
			TR 200000060 T2 21-09-2000
			TW 491845 B 21-06-2002
			US 6894051 B1 17-05-2005
			US 2002115858 A1 22-08-2002
			US 2005192284 A1 01-09-2005
			US 2006030568 A1 09-02-2006
			US 2007004746 A1 04-01-2007
			WO 9903854 A1 28-01-1999
			ZA 9806362 A 22-01-1999
WO 2008054609	A2	08-05-2008	US 2008132419 A1 05-06-2008
			WO 2008054609 A2 08-05-2008
WO 2004078163	A2	16-09-2004	CA 2514733 A1 16-09-2004
			EP 1631260 A2 08-03-2006
			JP 2007524596 A 30-08-2007
			WO 2004078163 A2 16-09-2004

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 3(completely); 1, 2, 4, 6, 8-15(partially)

Co-crystals according to claim 1 in which the co-crystal former is benzoic acid.

2. claims: 5, 7(completely); 1, 2, 4, 6, 8-15(partially)

Co-crystals according to claim 1 in which the co-crystal former is fumaric acid or succinic acid.
